Optimus U, Inc — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$202,522	2
2024	Research	$354,048	2
2023	Research	$446,004	1
2022	Research	$688,679	87
2021	Research	$841,242	433
2020	Research	$963,716	1

Breakdown

Who paid Research payments · program years 2020–2025

AstraZeneca Pharmaceuticals LP $2,408,044 6 payments
Novo Nordisk AS $610,403 517 payments
E.R. Squibb & Sons, L.L.C. $477,764 3 payments

Studies the money was for Research payments · program years 2020–2025

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacodynamic Effects of MEDI0382 in Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH) $1,868,681 3 payments
Nn9931-4553 $610,403 517 payments
COSMOS - A Phase IIa Randomized Double-blind Placebo-controlled Study to Evaluate the Safety Tolerability and Pharmacodynamics of AZD4831 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis $539,363 3 payments
Phase 2 PoC in Early AD Patients - A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimer s Disease (TargetT $275,241 1 payment
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) $202,522 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.